Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Press Release
Dianthus Therapeutics Ph. 2 MaGic Data Investor Webcast Sep 8, 2025 8:00 AM EDT Webcast Supporting Materials Claseprubart Phase 2 MaGic Data Presentation 1.6 MB
